Glyburide Advantage in Malignant Edema and Stroke Pilot (GAMES-PILOT)

• ClinicalTrials.gov Identifier: NCT01268683
• Recruitment Status: Completed
• First Posted: December 31, 2010
• Results First Posted: June 6, 2014
• Last Update Posted: August 6, 2021
• Sponsor: Biogen
• Collaborators: University of Maryland, College Park; Massachusetts General Hospital
• Information provided by (Responsible Party): Biogen

Tracking Information

• First Submitted Date: December 29, 2010
• First Posted Date: December 31, 2010
• Results First Submitted Date: March 11, 2014
• Results First Posted Date: June 6, 2014
• Last Update Posted Date: August 6, 2021
• Actual Study Start Date: May 26, 2011
• Actual Primary Completion Date: June 7, 2012 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: August 4, 2021)

• Rate of Enrollment [ Time Frame: Day 1 ]
  The number of months to enroll 10 participants.
• Percentage of Enrolled Participants to Screened Participants [ Time Frame: Day 1 ]
• Percentage of Participants Completing 90-Day Follow-Up [ Time Frame: Day 90 ]
• Percentage of Dose Reductions/ Dose Suspensions [ Time Frame: Up to Day 3 ]
• Percentage of Participants With All Four MRI Assessments Per Protocol [ Time Frame: Up to Day 3 ]
• Number of MRI Assessments Per Participant [ Time Frame: Up to Day 3 ]
• Percentage of Participants Requiring One or More Hypoglycemia Treatments [ Time Frame: Up to Day 4 ]
• Percentage of Participants With Pre-specified Adverse Events Associated With Glyburide According to Protocol [ Time Frame: Up to Day 4 ]

• Original Primary Outcome Measures (submitted: December 30, 2010): Feasibility of recruiting target population [ Time Frame: 6 months ]

Current Secondary Outcome Measures (submitted: August 4, 2021)

• Number of Participants With Adverse Events and Serious Adverse Events [ Time Frame: Up to Day 90 ]
  Adverse Events (AE's) of special interest (cardiac events, difficulty controlling blood sugar, liver problems, and blood disorders, including anemia) will be followed for 30 days and all Severe Adverse Events (SAE's) will be followed for 90 days. SAE's and AE's were reviewed, and the number of participants with unanticipated adverse events, or drug-related SAE's were assessed.
• Infarcted Hemisphere Volume [ Time Frame: Baseline, Day 1, Day 2, and Day 3 ]
• Absolute Diffusion Weighted Imaging (DWI) Lesion Volume [ Time Frame: Baseline, Day 1, Day 2, and Day 3 ]
• Change From Baseline in DWI Lesion Volume [ Time Frame: Baseline, Day 1, Day 2, and Day 3 (Day 3 reported) ]
• Midline Shift [ Time Frame: Baseline, Day 1, Day 2, and Day 3 ]
• Ipsilateral Ventricle Volume [ Time Frame: Baseline, Day 1, Day 2, and Day 3 ]
• Frequency of Hemorrhagic Events [ Time Frame: Day 1, Day 2, and Day 3 ]
• National Institute of Health Stroke Scale (NIHSS) Score [ Time Frame: Baseline, Day 1, Day 2, Day 3, and Day 7 ]
  The NIHSS is composed of 11 categories, each of which is scored between 0 and 4. A score of 0 indicates normal function, a higher score indicates more impairment. Category scores are summed to generate the total NIHSS score (possibles scores range from 0-42).
• Glasgow Coma Scale (GCS) Score [ Time Frame: Baseline, Day 1, Day 2, Day 3, and Day 7 ]
  The GCS is scored on a scale between 3 and 15 (3 = the worst, and 15 = best). It is composed of three parameters : Best Eye Response (scored on a scale of 1-4), Best Verbal Response (scored on a scale of 1-5), Best Motor Response (scored on a scale of 1-6)
• Full Outline of UnResponsiveness (FOUR) Score [ Time Frame: Baseline, Day 1, Day 2, Day 3, and Day 7 ]
  The FOUR Score is a 17-point scale (with potential scores ranging from 0 - 16). Decreasing FOUR Score is associated with worsening level of consciousness. The FOUR Score assesses four domains of neurological function: eye responses, motor responses, brainstem reflexes, and breathing pattern.
• Number of Participants Requiring Decompressive Craniectomy (DC) [ Time Frame: Up to Day 90 ]
• Number of Participants With a Modified Rankin Scale (mRS) Score ≤ 4 [ Time Frame: Day 30, Day 90 ]
  The mRS scale runs from 0-6, the scoring is as follows: 0 - No symptoms, 1 - No significant disability, 2 - Slight disability, 3 - Moderate disability, 4 - Moderately severe disability, 5 - Severe disability, 6 - Dead

Original Secondary Outcome Measures (submitted: December 30, 2010)

• Safety and tolerability [ Time Frame: 90 days ]
• Pharmacokinetics/pharmacodynamics [ Time Frame: 3 days ]
• Clinical and MRI outcome data [ Time Frame: 90 days ]

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Glyburide Advantage in Malignant Edema and Stroke Pilot
• Official Title: A Multi-Center, Prospective, Open Label, Phase IIa Trial of RP-1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Experience Clinically Significant Brain Swelling.
• Brief Summary: The primary objective of this study is to assess the feasibility of enrolling, evaluating, and treating with glyburide for injection severe anterior circulation ischemic stroke participants, whether or not treated with standard of care intravenous (IV) recombinant tissue plasminogen activator (rtPA). Participants must be between 18-80 years of age, must have a baseline diffusion weighted image (DWI) lesion volume 82 -210 centimeters cubed (cm3), and time from symptom onset to start of study infusion must be ≤10 hour(hr). The secondary objectives are to assess the initial safety and tolerability, and pharmacokinetics (PK) /pharmacodynamics (PD) of glyburide in severe stroke participants, as well as to compare the clinical and magnetic resonance imaging (MRI) outcome data to benchmark data derived from published literature.

Detailed Description

This is a multi-center, prospective, open label, phase IIa trial of glyburide for injection in 10 participants with a severe anterior circulation ischemic stroke who are likely to experience clinically significant brain swelling.

Participants will receive glyburide, delivered as an IV bolus followed by an IV infusion for 72 hours.

Participants will have a baseline (pretreatment) MRI scan as standard of care, and three follow up MRI scans (at 24+12 hours, 48+12 hours, and 72±12 hours). Since recanalization may have an effect on outcome, the results of vascular studies, obtained as part of standard of care and defined as CTA, MRA or catheter angiography of the head and neck, will be recorded. Additionally, clinical endpoints such as the National Institutes of Health Stroke Scale (NIHSS), Glasgow Coma Scale (GCS) and Full Outline of UnResponsiveness Score (FOUR) Score (baseline, 24±12 hour, 48±12 hour, 72±12 hour and 7±1 days) and Modified Rankin Scale (mRS) (30±5 days and 90±7 days) will be assessed. Safety parameters will be assessed through Day 7 or discharge (whichever is sooner), and then again at Day 30±5 and Day 90±7.

Study participation is expected to last 90±7 days.

This study was previously posted by Remedy Pharmaceuticals, Inc. and has since been acquired by Biogen.

• Study Type: Interventional
• Study Phase: Phase 1; Phase 2
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Ischemic Stroke

Intervention

Drug: Glyburide for Injection

Administered as specified in the treatment arm.

Other Names:

• RP-1127
• glibenclamide
• glybenclamide

Study Arms

Experimental: Glyburide for Injection

This arm is administered a glyburide bolus followed by continuous infusion of glyburide for 72 hours

Intervention: Drug: Glyburide for Injection

Publications *

• Kimberly WT, Battey TW, Pham L, Wu O, Yoo AJ, Furie KL, Singhal AB, Elm JJ, Stern BJ, Sheth KN. Glyburide is associated with attenuated vasogenic edema in stroke patients. Neurocrit Care. 2014 Apr;20(2):193-201. doi: 10.1007/s12028-013-9917-z.
• Sheth KN, Kimberly WT, Elm JJ, Kent TA, Yoo AJ, Thomalla G, Campbell B, Donnan GA, Davis SM, Albers GW, Jacobson S, del Zoppo G, Simard JM, Stern BJ, Mandava P. Exploratory analysis of glyburide as a novel therapy for preventing brain swelling. Neurocrit Care. 2014 Aug;21(1):43-51. doi: 10.1007/s12028-014-9970-2.
• Sheth KN, Kimberly WT, Elm JJ, Kent TA, Mandava P, Yoo AJ, Thomalla G, Campbell B, Donnan GA, Davis SM, Albers GW, Jacobson S, Simard JM, Stern BJ. Pilot study of intravenous glyburide in patients with a large ischemic stroke. Stroke. 2014 Jan;45(1):281-3. doi: 10.1161/STROKEAHA.113.003352. Epub 2013 Nov 5.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: December 30, 2010): 10
• Original Estimated Enrollment: Same as current
• Actual Study Completion Date: June 7, 2012
• Actual Primary Completion Date: June 7, 2012 (Final data collection date for primary outcome measure)

Eligibility Criteria

Key Inclusion Criteria:

• A clinical diagnosis of acute ischemic stroke in the MCA or MCA/ACA territory.
• Pre-morbid mRS 0 - 1.
• A baseline DWI lesion between 82 cm3 and 210 cm3 on MRI.
• Patients treated with IV rtPA should meet established criteria for IV rtPA administration in the 0-3 and 3-4.5 hr time periods, respectively.
• The time to the start of infusion of study compound must be ≤ 10 hr after time of symptom onset
• Age ≥18 years and ≤70 years.
• Provision of written informed consent by the patient or from a legally authorized representative according to institutional guidelines and national regulations.

Key Exclusion Criteria:

• Evidence from imaging or pre-enrollment investigation of any diagnosis other than acute ischemic stroke likely to cause the presenting symptoms and signs.
• Commitment to decompressive craniectomy (DC) prior to enrollment, or follow-ing enrollment and prior to start of study compound.
• Treatment with IA rtPA or by mechanical means for clot disruption or with hypo-thermia.
• Patients unable to tolerate MRI scanning, e.g. those with pacemakers or automatic defibrillators.
• Pre-morbid mRS ≥ 2.
• Clinical signs of herniation, e.g. one or two dilated, fixed pupils; unconsciousness (i.e., ≥ 2 on item 1a on the NIHSS); loss of other brain stem reflexes attributable to herniation according to the investigator's judgment.
• CT or MRI evidence of hemorrhage or anteroseptal/pineal shift greater ≥2 mm prior to enrollment.
• Rapidly improving symptoms.
• Severe renal disorder from the patient's history (e.g. dialysis) or eGFR of < 30 mL/min/1.73 m2.
• Severe liver disease or ALT, AST, or bilirubin >2 times normal.
• Blood glucose <55 mg/dL at enrollment or immediately prior to administration of RP-1127, or a clinically significant history of hypoglycemia.
• Diagnosis of decompensated heart failure (e.g. clinical diagnosis of pulmonary edema, chest x-ray consistent with heart failure, tachypnea > 20, etc.)
• Sulfonylurea treatment within 30 days.
• Known allergy to sulfa or specific allergy to sulfonylurea drugs.
• Known G6PD enzyme deficiency.
• Pregnancy or breast-feeding. Women must be either post-menopausal (judged by the investigator), permanently sterilized or, if of childbearing age, must have a negative test for pregnancy obtained before enrollment.
• Patients already enrolled in a non-observation-only stroke study, or with life-expectancy <3 months not related to current stroke, or those unlikely to be com-pliant with follow up.
• Patients who, in the opinion of the investigator, are not suitable for the study (reason to be documented).

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 80 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT01268683
• Other Study ID Numbers: RPI 201
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Biogen
• Original Responsible Party: Sven Jacobson, Chief Executive Officer, Remedy Pharmaceuticals Inc.
• Current Study Sponsor: Biogen
• Original Study Sponsor: Remedy Pharmaceuticals, Inc.

Collaborators

• University of Maryland, College Park
• Massachusetts General Hospital

Investigators

• Study Director: Medical Director; Biogen

• PRS Account: Biogen
• Verification Date: August 2021